The animals in phases 1 and 2 were challenged 185 and 199 dpv, respectively. In phase 1, 13 vaccinated and 5 control dogs were challenged, and, in the second phase, 12 vaccinated and 5 control animals were infected with the challenge virus. The diluted challenge virus administered had a titer of 103.6 MICLD50/mL. One (1.0) ml of this material was administered intramuscularly, with 0.5 mL in the right and left M. masseter each.
After the challenge virus inoculation, the dogs were monitored at least twice daily for clinical signs of rabies, and clinical scores were recorded, as described previously [38 (link)]. The animals were euthanised as soon as clinical score 2 or higher was reported.
Brain samples were taken for rabies diagnosis from each of the challenged animals that were euthanized after showing clinical signs and all remaining animals at the end of the 91-day period postinfection.
After the challenge virus inoculation, the dogs were monitored at least twice daily for clinical signs of rabies, and clinical scores were recorded, as described previously [38 (link)]. The animals were euthanised as soon as clinical score 2 or higher was reported.
Brain samples were taken for rabies diagnosis from each of the challenged animals that were euthanized after showing clinical signs and all remaining animals at the end of the 91-day period postinfection.
Free full text: Click here
